SCHEMBL3019573

SCHEMBL3019573

COc1ccc(S(=O)(=O)N2CCN(c3nc(Cc4cc(C)ccc4C)cs3)CC2)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.46
MAPT P10636 5/20 0.46
ALDH1A1 P00352 4/20 0.46
RECQL P46063 2/20 0.46
MCOLN3 Q8TDD5 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.42
USP2 O75604 3/20 0.42
HTT P42858 2/20 0.42
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KMT2A Q03164 3/20 0.42
GAA P10253 1/20 0.42
KDM4E B2RXH2 1/20 0.42
HSD17B10 Q99714 1/20 0.41
POLB P06746 1/20 0.40
TP53 P04637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017986 0.93 ALDH1A1 (0.55) MAPK1MAPTALDH1A1RECQLL3MBTL1
SCHEMBL2999651 0.90 MAPT (0.51) MAPK1MAPTALDH1A1RECQLL3MBTL1
SCHEMBL3013082 0.89 ALDH1A1 (0.46) MAPK1MAPTALDH1A1RECQLL3MBTL1
SCHEMBL3016750 0.89 MAPK1 (0.46) MAPK1MAPTALDH1A1RECQLMCOLN3
SCHEMBL3017745 0.88 L3MBTL1 (0.48) MAPK1MAPTALDH1A1RECQLL3MBTL1
SCHEMBL3013872 0.88 MAPT (0.47) MAPK1MAPTALDH1A1RECQLMCOLN3
SCHEMBL3009456 0.87 MAPT (0.52) MAPK1MAPTALDH1A1RECQLL3MBTL1
SCHEMBL3016964 0.87 MAPT (0.46) MAPK1MAPTALDH1A1RECQLMCOLN3
SCHEMBL3003817 0.87 ALDH1A1 (0.51) MAPTALDH1A1RECQLL3MBTL1USP2
SCHEMBL3007417 0.87 MAPT (0.46) MAPK1MAPTALDH1A1RECQLMCOLN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPK1 2767/4885MAPT 18/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.